The @UChicago campus is simply stunning right now! Reminded of this beautiful short story by O. Henry “The Last Leaf” about the sacrifices people make for the ones they love. americanenglish.state.gov/files/ae/resou…
Ben Derman
3,592 posts
Ben Derman
@bdermanmd
Asst Professor at UChicago, interim director myeloma program. I tweet about: Myeloma & MRD. linktr.ee/bderman
Chicago, IL
Joined June 2017
- In-vivo CAR Ts for myeloma are going to come fast and furious. These products are engineering marvels. ESO-T01 (EsoBiotec) is an anti-BCMA in-vivo CAR T that: 1) Delivers the CAR transgene to endogenous T-cells, reprogramming them to CAR T cells in situ 2) Overexpress CD47 to
- Cilta-cel associated Parkinsonism remains a challenge. Instead of going right to high dose Cy which can be toxic to circulating CAR T cells, we opted to try intrathecal chemotherapy in 5 consecutive cases. 4/5 pts had a response and 3 complete resolution! IT chemo seemed to be
- What happens when patients with myeloma and sustained MRD negativity choose to discontinue maintenance? We sought to answer this question in our study MRD2STOP, out now in @BloodCancerJnl nature.com/articles/s4140…
- What a difference 4 cycles of quadruplet induction can make in myeloma. Before (left) and after (right). Brings me so much joy! Next stop: MRD-negativity please. #mmsm
- A bit of personal news: I have joined the faculty @UCCancerCenter as part of the plasma cell disorders program. I am incredibly grateful to the many influential mentors who have guided me along the way & I will continue working toward making the lives of myeloma pts better!
- What does a 'cure' mean in multiple myeloma? Is it even possible? In this review, we first try to define a cure and then provide the evidence for why some patients may actually reach this milestone. First: our definition (see below). authors.elsevier.com/a/1f0qL,yeo3ud…
- 🧵 Top 10 ASCO 2025 Myeloma Abstracts – A Thread Here’s what stands out from this year’s abstracts - more to come after presentations! Updates in bispecifics, MRD-guided therapy, CAR-T, and trispecifics. 👇
- A liquid biopsy for myeloma may be closer than we think! Excited to share our work on MRD in the peripheral blood using mass spectrometry! We found mass spec may exceed the sensitivity of bone marrow based methods w/superior prognostication #mmsm #mmMRD bit.ly/MRDmyeloma
- What do you do when you need effective bridging therapy for pts w/myeloma waiting for CAR T-cell manufacture? Our awesome resident Dr. Marcus Marable @UChicagoMed reports on 'TurboCy' as effective bridging therapy! Delivered in 24 hours w/no central line!